Ser64
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser64  -  14-3-3 zeta (human)

Site Information
ssWRVVssIEQkTEG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 10407031

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , prostate cancer ( 1 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Pim1 (human) ( 1 )
Kinases, in vitro:
Pim1 (human) ( 1 )
Treatments:
SGI-1776 ( 1 )

Downstream Regulation
Effects of modification on 14-3-3 zeta:
activity, induced ( 1 ) , intracellular localization ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, induced ( 1 )
Induce interaction with:
AR (human) ( 1 ) , DNA ( 1 )

References 

1

Ruff SE, et al. (2021) PIM1 phosphorylation of the androgen receptor and 14-3-3 ΞΆ regulates gene transcription in prostate cancer. Commun Biol 4, 1221
34697370   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

5

Zhou J (2009) CST Curation Set: 5905; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info